FOLLICULAR LYMPHOMA

This study is testing a specific type of stem cell transplant using donated umbilical cord blood to treat patients with serious blood cancers and disorders. The procedure involves high-dose chemotherapy and radiation to wipe out the patient's diseased bone marrow before infusing …

This study is testing an immunotherapy drug called odronextamab in people with a specific type of slow-growing blood cancer (follicular lymphoma) who have not yet received any treatment and have a low amount of cancer. The goal is to see if this drug, which helps the body's own i…

This early-stage study is testing a new oral medication called LP-168 in adults whose B-cell blood cancers have returned or not responded to prior treatments. The main goals are to find the highest safe dose and understand how the drug moves through the body. Researchers will als…

This early-phase trial is testing a combination treatment for adults with B-cell lymphomas that have come back or stopped responding to standard therapies. The approach involves giving patients a daily oral drug (pirtobrutinib) before and after an infusion of their own geneticall…

This early-stage trial is testing a new experimental drug called IKS03 in adults with advanced B-cell non-Hodgkin lymphomas that have returned or stopped responding to standard treatments. The study aims to find the safest and most effective dose by first testing increasing amoun…

This study is testing whether a drug called mosunetuzumab, given alone or with another drug called zanubrutinib, is an effective first treatment for people with follicular lymphoma, a type of blood cancer. It will involve about 152 adults who have been recently diagnosed and have…

This study is testing a new type of treatment called EO2463, which is a therapeutic vaccine designed to teach the body's immune system to recognize and attack lymphoma cells. It will be given to patients with slow-growing non-Hodgkin's lymphoma, both by itself and in combination …

This study is testing a new type of cell therapy called CTX112 for people with B-cell blood cancers that have come back or not responded to other treatments. Doctors use CRISPR gene-editing technology to modify donor immune cells to better target and fight the cancer. The main go…

This large, late-stage trial is testing if adding a drug called obinutuzumab to standard radiotherapy works better at controlling early-stage follicular lymphoma and keeping it from coming back. It will enroll 190 adults with previously untreated, early-stage disease. The main go…

This study is testing whether combining two drugs—mosunetuzumab and lenalidomide—works better than current treatments for people newly diagnosed with certain slow-growing lymphomas. The trial will enroll 52 adults who haven't had any previous cancer treatment. Doctors will adjust…

This is a first-in-human study testing a new type of personalized immune cell therapy (CAR-T cells) for adults with Non-Hodgkin Lymphoma that has come back or stopped responding to standard treatments. The main goal is to find a safe dose of these modified immune cells, which are…

This study aims to understand how the drug zanubrutinib works for adults with certain blood cancers in everyday clinic settings, not a controlled trial. It will follow about 705 patients to see how the treatment affects their quality of life, how often they need hospital care, an…

This program provides access to a specialized immune cell therapy (CAR-T) for patients with certain lymphomas when their manufactured treatment doesn't meet regular commercial standards but still meets safety requirements for clinical use. It's designed for patients who cannot un…

This study is testing a new type of personalized cell therapy for adults whose B-cell blood cancers have come back or not responded to standard treatments. The therapy, called CAR-T, is engineered to attack cancer cells using two targets (CD19 and CD20) instead of one, which may …

This study is testing whether a very low dose of radiation therapy works as well as the standard, higher dose for people with early-stage, slow-growing B-cell lymphomas. Researchers want to see if the lower dose can control the cancer just as effectively while causing fewer side …

This study is testing whether a combination of two drugs, obinutuzumab and CC-99282, can effectively control a specific type of blood cancer called follicular lymphoma in people who have not yet received any treatment for it. The trial is for adults with a high amount of cancer i…

This study is testing whether the drug epcoritamab can help people with follicular lymphoma whose cancer did not completely disappear after their initial treatment. The drug works by activating the immune system to attack cancer cells. About 35 adults who had a partial response o…

This study follows 700 adults with advanced lymphoma who are receiving epcoritamab treatment as prescribed by their doctors. Researchers will track how well the treatment works in real-world settings across 12-20 countries. Participants will be monitored for up to 3 years during …

This study aims to collect long-term safety and effectiveness data for patients with various blood cancers who are already taking the drug ibrutinib and benefiting from it. It provides continued access to the medication for about 700 participants who were in previous ibrutinib st…

This study is testing a new oral medication called BGB-16673 for people with various B-cell cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe and effective dose and to see how well the drug shrinks tumors. It is for adults …

This early-stage study is testing a new, one-time gene therapy called VNX-101 for patients whose B-cell blood cancers have returned or not responded to other treatments. The therapy is designed to help the patient's own immune system continuously fight cancer cells. Researchers w…

This large, late-stage trial is testing whether a new drug called golcadomide, when combined with the existing drug rituximab, works better than current standard treatments for people with follicular lymphoma that has returned or stopped responding to prior therapy. The study wil…

This large, late-stage trial is testing whether adding a new drug called tazemetostat to a standard two-drug treatment helps people with follicular lymphoma live longer without their cancer getting worse. The study is for adults whose lymphoma has returned or stopped responding t…

This study is testing whether combining a personalized cell therapy called axicabtagene ciloleucel (a type of CAR T-cell therapy) with radiation treatment is safe for adults with follicular lymphoma that has returned or hasn't responded to at least two prior treatments. Researche…

This study is testing whether a combination of two drugs, mosunetuzumab and zanubrutinib, can help control follicular lymphoma that has returned or stopped responding to prior treatment. It will involve about 56 adults who have had at least one prior therapy. The main goal is to …

This is a first-in-human study to find a safe and effective dose of a new drug called ONM-501. The drug is injected directly into tumors and is being tested alone and in combination with an approved immunotherapy drug (cemiplimab) in adults with advanced cancers that have stopped…

This study is testing a new combination of two drugs, loncastuximab tesirine and rituximab, for adults with follicular lymphoma that has returned or not responded to prior treatments. The main goal is to see if this combination can lead to a complete disappearance of detectable c…

This early-stage study is testing a new antibody drug called AZD0486 in people with B-cell non-Hodgkin lymphoma that has returned or stopped responding to previous treatments. Researchers will give increasing doses to about 317 participants to find the safest amount and check for…

This study is testing whether combining two existing drugs—rituximab and zanubrutinib—is safe and effective for people with untreated slow-growing B-cell lymphomas. It will enroll 43 adults with either follicular lymphoma or marginal zone lymphoma who need systemic treatment. Res…

This is a first-in-human study to test the safety of a new oral drug called SGR-1505 in adults with various types of relapsed or hard-to-treat B-cell cancers, like non-Hodgkin lymphoma and chronic lymphocytic leukemia. The main goal is to find the highest dose patients can tolera…

This study is testing a new oral medication called AS-1763 for adults with certain blood cancers that have returned or stopped responding to at least two prior treatments. The main goals are to find a safe dose and see if the drug helps control the cancer. The trial will enroll a…

This is the first study in people to test a new drug called ABBV-319 for several types of blood cancer that have come back or stopped responding to other treatments. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it mig…

This study is testing whether a drug called emapalumab can prevent severe side effects that sometimes occur with CAR-T cell therapy, a powerful treatment for certain lymphomas. Researchers will give emapalumab to 28 adults with hard-to-treat lymphoma who are receiving CAR-T thera…

This early-stage trial is testing a new type of cell therapy for adults with certain blood cancers that have returned or not responded to standard treatments. Doctors modify a patient's own immune cells (T cells) in a lab to better recognize and attack cancer cells, then infuse t…

This study is testing whether a combination of three drugs—epcoritamab, zanubrutinib, and rituximab—is safe and effective for people whose follicular or marginal zone lymphoma has come back or hasn't responded to prior treatments. About 45 participants will receive the treatment …

This is an early-stage study testing the safety of a personalized cell therapy for adults with specific types of non-Hodgkin lymphoma that have come back or not responded to standard treatments. Doctors will modify a patient's own immune cells to better target and fight their can…

This study is testing the safety and effectiveness of combining two drugs, mosunetuzumab and lenalidomide, for people with follicular lymphoma, a type of blood cancer. It will involve about 237 participants who have either tried previous treatments or are newly diagnosed but need…

This is a first-in-human study testing the safety and early effectiveness of a new cell therapy called SynKIR-310. It is for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments, including other CAR-T therapies. The main goa…

This study is testing a new two-drug combination for adults who have not yet received treatment for follicular lymphoma, a type of slow-growing blood cancer. The goal is to see if adding a newer drug (epcoritamab) to a standard one (rituximab) is safe and more effective at contro…

This study aims to understand how follicular lymphoma, a type of blood cancer, naturally changes and progresses over time. Researchers will closely monitor 200 adults who have been diagnosed but have not yet started any treatment. By collecting blood, tissue, and scan data regula…

This study is testing a new artificial intelligence (AI) tool designed to help match people with advanced cancer to suitable clinical trials. It will enroll up to 50,000 patients to see if using this AI system makes it easier for patients to find and join trials. The researchers …

This study aims to understand how a cancer drug called venetoclax works in the body when it's given as a liquid made from crushed tablets. It will enroll up to 30 children and young adults with blood cancers who are already receiving this liquid form because they cannot swallow p…

This study aims to monitor the long-term health of 500 patients who have already received CAR-T cell therapy for various blood cancers in earlier trials. Researchers will follow these patients for up to 15 years to check for any late-developing side effects, such as new cancers o…

This study aims to find biological markers in blood and tissue that can help doctors choose the most effective first treatment for advanced follicular lymphoma. Researchers will analyze samples from 654 patients who previously participated in a treatment trial. The goal is to cre…

This study aims to understand how well lymphoma patients' immune systems respond to flu and COVID vaccines. Researchers will measure antibody levels and immune cells in 200 patients with various lymphoma types, comparing them over time. The goal is to learn how cancer treatments …

This study aims to understand if CAR-T therapy, a powerful cancer treatment, reduces the body's long-term protection from common vaccines like measles, mumps, and tetanus. Researchers will observe 45 adults with blood cancers, measuring their antibody levels before and after CAR-…